Ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension by 55%, according to recent study results.

United Therapeutics plans to file for approval of ralinepag as a treatment for pulmonary arterial hypertension (PAH) before the end of the year, after positive results in a phase 3 trial. The drug ...

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best penny stocks under $1 to buy right now. On February 23, Gossamer Bio announced topline results from its Phase 3 PROSERA study evaluating seralutinib ...

Thank you for standing by. My name is Dina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Gossamer Bio Inc. PROSERA Phase 3 Topline Results Call. ...

The MarketWatch News Department was not involved in the creation of this content. - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week ...

A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...

- Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, ...

The biggest stories of the day delivered to your inbox.

The United States will push forward with the next phase of its plan for peace in Gaza, moving toward "demilitarization, technocratic governance, and reconstruction," President Donald Trump's special ...

Abir Oufrid, Basma Aabboub, Diango Keita, Sara Nejjari, Samia El Hakym, Hafssa El Hilali, Chaymae Chbihi, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Samia Arifi ...

GOTHENBURG, Sweden, Dec. 8, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ...